Hua Medicine
02552
Company Profile
Business description
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC.
Contact
Lane 36, Xuelin Road
Hua Medicine, Building 2
Pudong New Area
Shanghai201203
CHNT: +86 2138101800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
168
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,963.50 | 29.20 | 0.33% |
CAC 40 | 7,833.46 | 1.12 | -0.01% |
DAX 40 | 24,133.26 | 84.24 | -0.35% |
Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
FTSE 100 | 9,096.17 | 24.14 | -0.26% |
HKSE | 25,562.13 | 173.78 | 0.68% |
NASDAQ | 21,108.32 | 50.36 | 0.24% |
Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
S&P 500 | 6,388.64 | 0.00 | 0.00% |
S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
SSE Composite Index | 3,597.94 | 4.28 | 0.12% |